Table 4.
Sensitivity analysis of the robust EM-CRMs with two, four, five, and six skeletons under scenario 2
| Number of skeletons |
Design | Recommendation percentage at dose level |
Average # toxicity |
Average # patients |
Average duration |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | None | |||||
| Scenario 2 | 0.06 | 0.08 | 0.10 | 0.15 | 0.30 | 0.45 | |||||
| 2 | EM-CRMSEL | 0.0 | 0.1 | 1.2 | 18.4 | 50.9 | 29.4 | 0.0 | 8.4 | 36.0 | 21.8 |
| # patients | 4.1 | 3.4 | 4.1 | 6.8 | 9.4 | 8.1 | |||||
| EM-CRMAVG | 0.0 | 0.1 | 1.4 | 15.5 | 52.5 | 30.5 | 0.1 | 8.5 | 36.0 | 21.7 | |
| # patients | 4.2 | 3.4 | 4.1 | 6.6 | 9.3 | 8.3 | |||||
| 4 | EM-CRMSEL | 0.0 | 0.1 | 1.6 | 17.1 | 53.5 | 27.8 | 0.1 | 8.3 | 36.0 | 21.7 |
| # patients | 4.2 | 3.4 | 4.4 | 7.0 | 9.5 | 7.5 | |||||
| EM-CRMAVG | 0.0 | 0.3 | 2.0 | 16.9 | 54.1 | 26.7 | 0.1 | 8.1 | 36.0 | 21.7 | |
| # patients | 4.2 | 3.6 | 4.7 | 6.8 | 9.6 | 7.1 | |||||
| 5 | EM-CRMSEL | 0.0 | 0.1 | 1.0 | 13.5 | 58.2 | 27.2 | 0.0 | 8.4 | 36.0 | 21.7 |
| # patients | 4.2 | 3.4 | 4.1 | 6.5 | 10.6 | 7.3 | |||||
| EM-CRMAVG | 0.0 | 0.2 | 1.3 | 14.7 | 58.2 | 25.5 | 0.1 | 8.1 | 36.0 | 21.7 | |
| # patients | 4.2 | 3.5 | 4.5 | 6.5 | 10.5 | 6.7 | |||||
| 6 | EM-CRMSEL | 0.0 | 0.1 | 1.1 | 13.9 | 58.1 | 26.7 | 0.0 | 8.4 | 36.0 | 21.7 |
| # patients | 4.2 | 3.4 | 4.1 | 6.3 | 10.7 | 7.3 | |||||
| EM-CRMAVG | 0.0 | 0.1 | 1.4 | 14.9 | 56.9 | 26.5 | 0.2 | 8.2 | 36.0 | 21.7 | |
| # patients | 4.2 | 3.5 | 4.5 | 6.4 | 10.2 | 7.2 | |||||